New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
06:03 EDTVNDAVanda pullback a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the post-earnings pullback in shares of Vanda Pharmaceuticals as a buying opportunity. Piper says Hetlioz is launching well and that it sees no reason to back off its bullish stance or $25 price target. The firm reiterates an Overweight rating on the name.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
19:32 EDTVNDAOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTVNDAVanda raises FY15 Hetlioz, Fanapt sales to $100M-$115M from $95M-$110M
FY15 revenue consensus is $104.18M. Sees Hetlioz sales $40M-$45M. Raises Fanapt sales to $60M-$70M from $55M-$65M.
16:18 EDTVNDAVanda reports Q2 adjusted EPS (1c), may not compare to two estimates (29c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use